BMS-986012 + carboplatin + etoposide

BMS-986012 + carboplatin + etoposide is an investigational **combination therapy** studied primarily for **first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)**. BMS-986012 is a first-in-class, fully human IgG1 **monoclonal antibody** targeting the tumor-associated antigen **fucosyl-GM1 (Fuc-GM1)**, which is highly expressed on small cell lung cancer cells but minimally on normal tissues. This antibody is engineered to be non-fucosylated, enhancing its ability to induce **antibody-dependent cell-mediated cytotoxicity (ADCC)**, **complement-dependent cytotoxicity (CDC)**, and **antibody-dependent cellular phagocytosis (ADCP)**, thereby directing immune-mediated killing of tumor cells. **Carboplatin** and **etoposide** are established cytotoxic chemotherapeutics that function through DNA damage and inhibition of DNA synthesis and repair. The rationale for the combination is to leverage the immune-mediated specificity of BMS-986012 with the broad cytotoxicity of platinum-based chemotherapy, aiming for additive or synergistic anti-tumor effects in ES-SCLC. The development of this regimen is led by **Bristol Myers Squibb**, and trials have also explored quadruple combination with nivolumab (not included in this triplet), but the specific regimen queried here is the triplet drug combination for newly diagnosed ES-SCLC[1][2][3][4].